Joel W. Hay, PhD

Title(s)Professor Of Pharmaceutical Economics & Policy
AddressVPD 214-L
University Park Campus
Los Angeles CA 90089-3333
Phone+1 818 338 5433
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Joel W. Hay is Professor and Founding Chair in the Department of Pharmaceutical Economics and Policy in the School of Pharmacy, with a joint appointment in the Department of Economics and in the Leonard Schaeffer Center for Health Policy and Economics at the University of Southern California. He also serves as the USC Project Coordinator for the Rand Evidence-Based Medicine Practice Centers of Southern California funded by the US Agency for Health Research and Quality, and Co-Investigator at the USC Alzheimer Research Center funded by the California Dept. of Health Services. He is a Health Economics Research Scholar at the UCLA Center for Vaccine Research. He is a founding Executive Board member of the American Society for Health Economics and of the International Society for Pharmaceutical Economics and Outcomes Research.

    His previous positions include: Senior Research Fellow, the Hoover Institution, Stanford University (1985-1992); Senior Policy Analyst, Project HOPE (1983-1985); Asst. Professor, Dept. of Behavioral Sciences and Community Health, and Dept. of Economics, University of Connecticut (1980-1984); and Asst. Research Professor, University of Southern California (1978-1980). . He received his B.A. summa cum laude from Amherst College in 1974 and his M.A. (1975), M. Ph. (1976) and Ph.D. in economics (1980) from Yale University.

    Dr. Hay has authored or coauthored over 400 peer-reviewed scientific articles, abstracts, editorials and reports in the fields of pharmaceutical economics, health economics, outcomes research, disease management, statistics, econometrics, epidemiology and health care in journals including more than 160 peer-reviewed scientific articles in journals such as: American Journal of Cardiology, American Journal of Health-Systems Pharmacy, American Journal of Managed Care, American Journal of Public Heath, Archives of Neurology, Haemophilia, Health Care Financing Review, Health Policy, JAMA, Journal of AIDS, Journal of the American Geriatrics Society, Journal of Business & Economic Statistics, Journal of Clinical Gastroenterology, Journal of Health Economics, Journal of Health Politics, Policy and Law, Journal of Human Resources, Journal of the Royal Statistical Association, Medical Care, Pediatrics and Value in Health.

    Dr. Hay has served as a consultant to U.S. Centers for Medicare and Medicaid Services, U.S. Agency for Healthcare Research and Quality, U.S. Centers for Disease Control and Prevention, U.S. Public Health Service, U.S. Food and Drug Administration, U.S. Environmental Protection Agency, Government of Hungary, Hong Kong Centre for Economic Research, Hong Kong Medical Executives Association, World Bank, California AIDS Commission, California Medi-Cal Drug Advisory Board, County of San Diego Medically Indigent Adult program, and County of Sacramento Homeless Program. Dr. Hay has also written numerous health-related editorials published in papers such as Los Angeles Times, New York Times, Wall Street Journal, San Francisco Chronicle, San Diego Union, Sacramento Bee and Newsday.

    Dr. Hay has served as a Member of the Expert Advisory Panel on Drug Utilization Review, United States Pharmacopeial Convention; an Executive Committee member for the federally-sponsored Southern California Evidence-Based Medicine Practice Center; and a member of the JAMA Web Site HIV/AIDS Editorial Review Panel. Dr. Hay is a founding member of the Board of Directors of the International Society for Pharmacoeconomics and Outcomes Research. He has recently completed a study of hospital and pharmaceutical costs for the national Blue Cross Blue Shield Association (http://bcbshealthissues.com/costpressconf/materials.vtml). This report has been discussed in several national media, including NPR, CSPAN, USA Today, US News and World Report and others.

    Joel Hay was Founding Editor-in-Chief of Value in Health the peer-reviewed scientific journal of the International Society for Pharmacoeconomics and Outcomes Research until 2003. This journal, started in 1998, became Medline-listed in 2002. In its first impact factor, Value in Health was ranked #1 in two categories for the year 2004, by the ISI Journal Citation Reports® (JCR) with an impact factor of 3.657. Value in Health led all other journals listed both in the Health Care Sciences and Services category in the JCR Science Edition and in the Health Policy & Services category in the JCR Social Sciences Edition.

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Neonates with mild hypoxic-ischaemic encephalopathy receiving supportive care versus therapeutic hypothermia in California. Arch Dis Child Fetal Neonatal Ed. 2021 Aug 30. Yieh L, Lee H, Lu T, Song A, Gong CL, Wu TW, Friedlich P, Lakshmanan A, Dukhovny D, Hay J. PMID: 34462319.
      View in: PubMed   Mentions:    Fields:    
    2. Diagnosing newborns with suspected mitochondrial disorders: an economic evaluation comparing early exome sequencing to current typical care. Genet Med. 2021 Oct; 23(10):1854-1863. Crawford SA, Gong CL, Yieh L, Randolph LM, Hay JW. PMID: 34040192.
      View in: PubMed   Mentions:    Fields:    
    3. Where Do We Go From Here? A Framework for Using Susceptible-Infectious-Recovered Models for Policy Making in Emerging Infectious Diseases. Value Health. 2021 07; 24(7):917-924. Zawadzki RS, Gong CL, Cho SK, Schnitzer JE, Zawadzki NK, Hay JW, Drabo EF. PMID: 34243834.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    4. Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection. Clin Microbiol Infect. 2021 Oct; 27(10):1448-1454. Chen J, Gong CL, Hitchcock MM, Holubar M, Deresinski S, Hay JW. PMID: 33878506.
      View in: PubMed   Mentions:    Fields:    
    5. A US Population Health Survey on the Impact of COVID-19 Using the EQ-5D-5L. J Gen Intern Med. 2021 05; 36(5):1292-1301. Hay JW, Gong CL, Jiao X, Zawadzki NK, Zawadzki RS, Pickard AS, Xie F, Crawford SA, Gu NY. PMID: 33686587.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansPHPublic Health
    6. Validating the Importance of Positive Childhood Experiences on Adult Mental Health. JAMA Pediatr. 2021 Feb 01; 175(2):204. Gong CL, Yieh L, Hay JW. PMID: 32250426.
      View in: PubMed   Mentions:    Fields:    
    7. The Assessment of Different Diets and Mortality Fails to Address Unmeasured Confounding. JAMA Intern Med. 2021 Jan 01; 181(1):137-138. Gong CL, Zawadzki NK, Hay JW. PMID: 33196780.
      View in: PubMed   Mentions:    Fields:    
    8. Characterizing the Validity and Real-World Utility of Health Technology Assessments in Healthcare: Future Directions Comment on "Problems and Promises of Health Technologies: The Role of Early Health Economic Modelling". Int J Health Policy Manag. 2020 08 01; 9(8):352-355. Zawadzki NK, Hay JW. PMID: 32613807.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    9. Reconstruction After Salvage Total Laryngectomy: A Cost-effectiveness Analysis. Otolaryngol Head Neck Surg. 2021 01; 164(1):139-145. Acevedo JR, Yu JC, Cameron B, Nurimba M, Hay JW, Kokot NC. PMID: 32660337.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    10. Outcomes and Utilization of Adjuvant Chemotherapy for Stage II Colon Cancer in the Oxaliplatin Period: A SEER-Medicare Analysis. Am J Clin Oncol. 2020 06; 43(6):428-434. Jiao X, Hay JW, Sadeghi S, Barzi A. PMID: 32187027.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    11. Unprocessed Red Meat and Processed Meat Consumption. Ann Intern Med. 2020 05 05; 172(9):637-638. Gong CL, Zawadzki NK, Zawadzki R, Tran J, Hay JW. PMID: 32365370.
      View in: PubMed   Mentions:    Fields:    
    12. There is Insufficient Evidence to Support a Causal Relationship Between Chili Pepper Consumption and Mortality. J Am Coll Cardiol. 2020 04 21; 75(15):1864. Zawadzki NK, Gong CL, Cho SK, Hay JW. PMID: 32299600.
      View in: PubMed   Mentions: 1     Fields:    Translation:Animals
    13. Cost-Effectiveness Analysis of Four Common Diagnostic Methods for Clostridioides difficile Infection. J Gen Intern Med. 2020 04; 35(4):1102-1110. Xuan S, Zangwill KM, Ni W, Ma J, Hay JW. PMID: 32016703.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    14. Hypertension and Unlikely Causality in the Association Between Soft Drink Consumption and Mortality. JAMA Intern Med. 2020 02 01; 180(2):335-336. Hay JW, Zawadzki NK, Zawadzki R. PMID: 32011633.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    15. Now Is the Time for Transparency in Value-Based Healthcare Decision Modeling. Value Health. 2019 05; 22(5):564-569. Hay JW. PMID: 31104735.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    16. Early onset sepsis calculator-based management of newborns exposed to maternal intrapartum fever: a cost benefit analysis. J Perinatol. 2019 04; 39(4):571-580. Gong CL, Dasgupta-Tsinikas S, Zangwill KM, Bolaris M, Hay JW. PMID: 30692615.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    17. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients. Pharmacotherapy. 2019 02; 39(2):118-128. Aliyev ER, Hay JW, Hwang C. PMID: 30565265.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    18. Cost-effectiveness of rivaroxaban versus warfarin for treatment of nonvalvular atrial fibrillation in patients with worsening renal function. Int J Cardiol. 2019 May 01; 282:53-58. Salcedo J, Hay JW, Lam J. PMID: 30518479.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    19. Impact of drug substitution on cost of care: an example of economic analysis of cetuximab versus panitumumab. Cost Eff Resour Alloc. 2018; 16:30. Xu Y, Hay JW, Barzi A. PMID: 30459532.
      View in: PubMed   Mentions:
    20. Cost-effectiveness Analysis of Sequential Treatment of Abaloparatide Followed by Alendronate Versus Teriparatide Followed by Alendronate in Postmenopausal Women With Osteoporosis in the United States. Ann Pharmacother. 2019 02; 53(2):134-143. Le QA, Hay JW, Becker R, Wang Y. PMID: 30160186.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    21. A cost-effectiveness analysis of reslizumab in the treatment of poorly controlled eosinophilic asthma. J Asthma. 2019 Aug; 56(8):872-881. Lam J, Hay JW, Salcedo J, Kenyon NJ. PMID: 30003833.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    22. Cost-effectiveness Analysis of Regorafenib and TAS-102 in Refractory Metastatic Colorectal Cancer in the United States. Clin Colorectal Cancer. 2018 12; 17(4):e751-e761. Cho SK, Hay JW, Barzi A. PMID: 30228027.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    23. First-line pembrolizumab in PD-L1 positive non-small-cell lung cancer: A cost-effectiveness analysis from the UK health care perspective. Lung Cancer. 2018 09; 123:166-171. Hu X, Hay JW. PMID: 30089590.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    24. Behavioral Economics Interventions to Improve Outpatient Antibiotic Prescribing for Acute Respiratory Infections: a Cost-Effectiveness Analysis. J Gen Intern Med. 2019 06; 34(6):846-854. Gong CL, Zangwill KM, Hay JW, Meeker D, Doctor JN. PMID: 29740788.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    25. Comparative Effectiveness of a Technology-Facilitated Depression Care Management Model in Safety-Net Primary Care Patients With Type 2 Diabetes: 6-Month Outcomes of a Large Clinical Trial. J Med Internet Res. 2018 04 23; 20(4):e147. Wu S, Ell K, Jin H, Vidyanti I, Chou CP, Lee PJ, Gross-Schulman S, Sklaroff LM, Belson D, Nezu AM, Hay J, Wang CJ, Scheib G, Di Capua P, Hawkins C, Liu P, Ramirez M, Wu BW, Richman M, Myers C, Agustines D, Dasher R, Kopelowicz A, Allevato J, Roybal M, Ipp E, Haider U, Graham S, Mahabadi V, Guterman J. PMID: 29685872.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    26. Cost-Effectiveness of a Technology-Facilitated Depression Care Management Adoption Model in Safety-Net Primary Care Patients with Type 2 Diabetes. Value Health. 2018 05; 21(5):561-568. Hay JW, Lee PJ, Jin H, Guterman JJ, Gross-Schulman S, Ell K, Wu S. PMID: 29753353.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    27. Lifestyle intervention for adults with spinal cord injury: Results of the USC-RLANRC Pressure Ulcer Prevention Study. J Spinal Cord Med. 2019 01; 42(1):2-19. Carlson M, Vigen CLP, Rubayi S, Blanche EI, Blanchard J, Atkins M, Bates-Jensen B, Garber SL, Pyatak EA, Diaz J, Florindez LI, Hay JW, Mallinson T, Unger JB, Azen SP, Scott M, Cogan A, Clark F. PMID: 28414254.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    28. Prescriber preferences for behavioural economics interventions to improve treatment of acute respiratory infections: a discrete choice experiment. BMJ Open. 2016 Sep 22; 6(9):e012739. Gong CL, Hay JW, Meeker D, Doctor JN. PMID: 27660322.
      View in: PubMed   Mentions: 5     Fields:    
    29. A Cost-effectiveness Analysis of Preexposure Prophylaxis for the Prevention of HIV Among Los Angeles County Men Who Have Sex With Men. Clin Infect Dis. 2016 Dec 01; 63(11):1495-1504. Drabo EF, Hay JW, Vardavas R, Wagner ZR, Sood N. PMID: 27558571.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansPHPublic Health
    30. Effect of Behavioral Interventions on Inappropriate Antibiotic Prescribing Among Primary Care Practices: A Randomized Clinical Trial. JAMA. 2016 Feb 09; 315(6):562-70. Meeker D, Linder JA, Fox CR, Friedberg MW, Persell SD, Goldstein NJ, Knight TK, Hay JW, Doctor JN. PMID: 26864410.
      View in: PubMed   Mentions: 178     Fields:    Translation:Humans
    31. A Budget Impact Model of Hemophilia Bypassing Agent Prophylaxis Relative to Recombinant Factor VIIa On-Demand. J Manag Care Spec Pharm. 2016 Feb; 22(2):149-57. Mehta DA, Oladapo AO, Epstein JD, Novack AR, Neufeld EJ, Hay JW. PMID: 27015254.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    32. Understanding patient preferences and willingness to pay for hemophilia therapies. Patient Prefer Adherence. 2015; 9:1623-30. Chaugule SS, Hay JW, Young G. PMID: 26635471.
      View in: PubMed   Mentions:
    33. Promise of Precision Medicine. JAMA. 2015 Oct 27; 314(16):1752. Chen CX, Hay JW. PMID: 26505605.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    34. Factors Associated with Failure to Achieve SVR in Hepatitis C Genotype 3 Patients Within an Integrated Care Delivery System. J Manag Care Spec Pharm. 2015 Aug; 21(8):641-7. Cheetham TC, Niu F, Chiang K, Yuan Y, Kalsekar A, Hechter R, Hay JW, Nyberg L. PMID: 26233536.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    35. Marijuana use in models for health outcomes. Am J Med. 2015 Mar; 128(3):e23. Thompson CA, Hay JW. PMID: 25707892.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    36. Estimating the association between metabolic risk factors and marijuana use in U.S. adults using data from the continuous National Health and Nutrition Examination Survey. Ann Epidemiol. 2015 Jul; 25(7):486-91. Thompson CA, Hay JW. PMID: 25743435.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    37. Estimates of utility weights in hemophilia: implications for cost-utility analysis of clotting factor prophylaxis. Expert Rev Pharmacoecon Outcomes Res. 2015 Apr; 15(2):267-83. Grosse SD, Chaugule SS, Hay JW. PMID: 25585817.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    38. Cost effectiveness of fingolimod, teriflunomide, dimethyl fumarate and intramuscular interferon-β1a in relapsing-remitting multiple sclerosis. CNS Drugs. 2015 Jan; 29(1):71-81. Zhang X, Hay JW, Niu X. PMID: 25326785.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    39. Cost-effectiveness analysis of alternative screening and treatment strategies for heterozygous familial hypercholesterolemia in the United States. Int J Cardiol. 2015 Feb 15; 181:417-24. Chen CX, Hay JW. PMID: 25569270.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    40. A review of the economic burden of glioblastoma and the cost effectiveness of pharmacologic treatments. Pharmacoeconomics. 2014 Dec; 32(12):1201-12. Messali A, Villacorta R, Hay JW. PMID: 25085219.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    41. Impact of Maternal Education on Child Immunization Propensity in China. Value Health. 2014 Nov; 17(7):A724-5. Ding Y, Hay J. PMID: 27202575.
      View in: PubMed   Mentions: 2     Fields:    
    42. Cost-effectiveness analysis of abiraterone and sipuleucel-T in asymptomatic metastatic castration-resistant prostate cancer. J Natl Compr Canc Netw. 2014 Oct; 12(10):1417-25. Gong CL, Hay JW. PMID: 25313181.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    43. Novel methods of measuring clinical outcomes from psoriasis and psoriatic arthritis clinical trials. Expert Rev Pharmacoecon Outcomes Res. 2014 Aug; 14(4):545-58. Villacorta R, Hay JW, Messali A. PMID: 24820676.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    44. Implementing trials of complex interventions in community settings: the USC-Rancho Los Amigos pressure ulcer prevention study (PUPS). Clin Trials. 2014 Apr; 11(2):218-29. Clark F, Pyatak EA, Carlson M, Blanche EI, Vigen C, Hay J, Mallinson T, Blanchard J, Unger JB, Garber SL, Diaz J, Florindez LI, Atkins M, Rubayi S, Azen SP, PUPS Study Group . PMID: 24577972.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    45. Cost-effectiveness of adding bevacizumab to first line therapy for patients with advanced ovarian cancer. Gynecol Oncol. 2014 Mar; 132(3):677-83. Mehta DA, Hay JW. PMID: 24463160.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    46. Cost-effectiveness analysis of the bivalent and quadrivalent human papillomavirus vaccines from a societal perspective in Colombia. PLoS One. 2013; 8(11):e80639. Aponte-González J, Fajardo-Bernal L, Diaz J, Eslava-Schmalbach J, Gamboa O, Hay JW. PMID: 24260441.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCellsPHPublic Health
    47. Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States. Pharmacoeconomics. 2013 Sep; 31(9):823-39. Villacorta R, Hay JW, Messali A. PMID: 23975739.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    48. Long term healthcare costs of infants who survived neonatal necrotizing enterocolitis: a retrospective longitudinal study among infants enrolled in Texas Medicaid. BMC Pediatr. 2013 Aug 20; 13:127. Ganapathy V, Hay JW, Kim JH, Lee ML, Rechtman DJ. PMID: 23962093.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    49. The cost-effectiveness of temozolomide in the adjuvant treatment of newly diagnosed glioblastoma in the United States. Neuro Oncol. 2013 Nov; 15(11):1532-42. Messali A, Hay JW, Villacorta R. PMID: 23935155.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    50. Effects of medicaid on clinical outcomes. N Engl J Med. 2013 08 08; 369(6):581-2. Hay JW. PMID: 23924020.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    51. Risk of all-cause hospitalization in COPD patients initiating long-acting or short-acting beta agonist therapy. J Med Econ. 2013 Aug; 16(8):1082-8. Bollu V, Ejzykowicz F, Rajagopalan K, Karafilidis J, Hay JW. PMID: 23777224.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    52. Bypass therapy assay testing as a strategy to reduce costs for treatment of haemophilia patients with inhibitors. Haemophilia. 2013 Sep; 19(5):711-9. Hay JW, Chaugule SC, Young G. PMID: 23672765.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    53. Cost-benefit analysis of hospital based postpartum vaccination with combined tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis vaccine (Tdap). Vaccine. 2013 May 24; 31(22):2558-64. Ding Y, Yeh SH, Mink CA, Zangwill KM, Allred NJ, Hay JW. PMID: 23583811.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    54. Costs and benefits of male circumcision. JAMA Pediatr. 2013 Feb; 167(2):198. Hay JW. PMID: 23381456.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    55. What is more valuable: fenofibrate patents or fenofibrate clinical outcomes? Arch Intern Med. 2012 Oct 22; 172(19):1521-2; author reply 1522-3. Hay JW. PMID: 23090194.
      View in: PubMed   Mentions:    Fields:    
    56. Incremental expenditure of biologic disease modifying antirheumatic treatment using instrumental variables in panel data. Health Econ. 2013 Jul; 22(7):807-23. Kawatkar AA, Hay JW, Stohl W, Nichol MB. PMID: 22718267.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    57. Comparative effectiveness of statin plus fibrate combination therapy and statin monotherapy in patients with type 2 diabetes: use of propensity-score and instrumental variable methods to adjust for treatment-selection bias. Pharmacoepidemiol Drug Saf. 2012 May; 21(5):470-84. Suh HS, Hay JW, Johnson KA, Doctor JN. PMID: 22461130.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    58. Cost-benefit analysis of in-hospital influenza vaccination of postpartum women. Obstet Gynecol. 2012 Feb; 119(2 Pt 1):306-14. Ding Y, Zangwill KM, Hay JW, Allred NJ, Yeh SH. PMID: 22270282.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansPHPublic Health
    59. Efficacy of bypassing agents in patients with hemophilia and inhibitors: a systematic review and meta-analysis. Clin Ther. 2012 Feb; 34(2):434-45. Zhou ZY, Hay JW. PMID: 22285208.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    60. Cost-effectiveness analysis of collaborative care management of major depression among low-income, predominantly Hispanics with diabetes. Value Health. 2012 Mar-Apr; 15(2):249-54. Hay JW, Katon WJ, Ell K, Lee PJ, Guterman JJ. PMID: 22433755.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    61. Costs of necrotizing enterocolitis and cost-effectiveness of exclusively human milk-based products in feeding extremely premature infants. Breastfeed Med. 2012 Feb; 7(1):29-37. Ganapathy V, Hay JW, Kim JH. PMID: 21718117.
      View in: PubMed   Mentions: 56     Fields:    Translation:HumansAnimals
    62. Systematic literature review of economics analysis on treatment of mild-to-moderate bleeds with aPCC versus rFVIIa. J Med Econ. 2011; 14(4):516-25. Hay JW, Zhou ZY. PMID: 21699366.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    63. Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors. Haemophilia. 2011 Sep; 17(5):e969-74. Hay JW, Zhou ZY. PMID: 21649802.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    64. Effectiveness of a lifestyle intervention in promoting the well-being of independently living older people: results of the Well Elderly 2 Randomised Controlled Trial. J Epidemiol Community Health. 2012 Sep; 66(9):782-90. Clark F, Jackson J, Carlson M, Chou CP, Cherry BJ, Jordan-Marsh M, Knight BG, Mandel D, Blanchard J, Granger DA, Wilcox RR, Lai MY, White B, Hay J, Lam C, Marterella A, Azen SP. PMID: 21636614.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    65. Antidepressant use in geriatric populations: the burden of side effects and interactions and their impact on adherence and costs. Am J Geriatr Psychiatry. 2011 Mar; 19(3):211-21. Mark TL, Joish VN, Hay JW, Sheehan DV, Johnston SS, Cao Z. PMID: 21425504.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    66. Effectiveness of collaborative care in addressing depression treatment preferences among low-income Latinos. Psychiatr Serv. 2010 Nov; 61(11):1112-8. Dwight-Johnson M, Lagomasino IT, Hay J, Zhang L, Tang L, Green JM, Duan N. PMID: 21041350.
      View in: PubMed   Mentions: 25     Fields:    Translation:Humans
    67. Adverse events and intravenous versus oral bisphosphonate use in patients with osteoporosis and cancer in the U.S. Gen Dent. 2010 Nov-Dec; 58(6):484-92; quiz 493-4. Skrepnek GH, Seal B, Tangirala M, Jeffcoat MK, Watts NB, Hay JW. PMID: 21062718.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    68. Cost and resource utilization comparisons of second-generation antihistamines vs. montelukast for allergic rhinitis treatment. Allergy Asthma Proc. 2009 Nov-Dec; 30(6):634-42. Hay J, Jhaveri M, Tangirala M, Kaliner M. PMID: 20031009.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    69. Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I. Value Health. 2010 Jan-Feb; 13(1):3-7. Hay JW, Smeeding J, Carroll NV, Drummond M, Garrison LP, Mansley EC, Mullins CD, Mycka JM, Seal B, Shi L. PMID: 19874571.
      View in: PubMed   Mentions: 22     Fields:    Translation:Humans
    70. Good research practices for measuring drug costs in cost-effectiveness analyses: a managed care perspective: the ISPOR Drug Cost Task Force report--Part III. Value Health. 2010 Jan-Feb; 13(1):14-7. Mansley EC, Carroll NV, Chen KS, Shah ND, Piech CT, Hay JW, Smeeding J. PMID: 19883404.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    71. Good research practices for measuring drug costs in cost effectiveness analyses: an industry perspective: the ISPOR Drug Cost Task Force report--Part V. Value Health. 2010 Jan-Feb; 13(1):25-7. Mycka JM, Dellamano R, Kolassa EM, Wonder M, Ghosh S, Hay JW, Smeeding J. PMID: 19883402.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    72. Good research practices for measuring drug costs in cost-effectiveness analyses: an international perspective: the ISPOR Drug Cost Task Force report--Part VI. Value Health. 2010 Jan-Feb; 13(1):28-33. Shi L, Hodges M, Drummond M, Ahn J, Li SC, Hu S, Augustovski F, Hay JW, Smeeding J. PMID: 19883403.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    73. Good research practices for measuring drug costs in cost-effectiveness analyses: a societal perspective: the ISPOR Drug Cost Task Force report--Part II. Value Health. 2010 Jan-Feb; 13(1):8-13. Garrison LP, Mansley EC, Abbott TA, Bresnahan BW, Hay JW, Smeeding J. PMID: 19883405.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    74. Good research practices for measuring drug costs in cost-effectiveness analyses: Medicare, Medicaid and other US government payers perspectives: the ISPOR Drug Cost Task Force report--Part IV. Value Health. 2010 Jan-Feb; 13(1):18-24. Mullins CD, Seal B, Seoane-Vazquez E, Sankaranarayanan J, Asche CV, Jayadevappa R, Lee WC, Romanus DK, Wang J, Hay JW, Smeeding J. PMID: 19807903.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    75. Commentary on Knight et al.: A systematic review of the cost-effectiveness of rFVIIa and APCC in the treatment of minor/moderate bleeding episodes for haemophilia patients with inhibitors. Haemophilia. 2010 Mar; 16(2):366-8; discussion 369-71. Hay JW, Zhou ZY. PMID: 19811544.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    76. Costs of second-generation antihistamines in the treatment of allergic rhinitis: US perspective. Curr Med Res Opin. 2009 Jun; 25(6):1421-31. Hay JW, Kaliner MA. PMID: 19422280.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    77. Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. Cancer. 2009 Feb 01; 115(3):489-98. Le QA, Hay JW. PMID: 19117341.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    78. The effect of patient satisfaction with pharmacist consultation on medication adherence: an instrumental variable approach. Pharm Pract (Granada). 2008 Oct; 6(4):201-10. Gu NY, Gai Y, Hay JW. PMID: 25157295.
      View in: PubMed   Mentions:
    79. Using pharmacoeconomics to value pharmacotherapy. Clin Pharmacol Ther. 2008 Aug; 84(2):197-200. Hay JW. PMID: 18679182.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    80. Cost impact of diagnostic imaging for lower extremity peripheral vascular occlusive disease. Value Health. 2009 Mar-Apr; 12(2):262-6. Hay JW, Lawler E, Yucel K, Guo A, Balzer T, Gaziano JM, Scranton RE. PMID: 18657093.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    81. Where do I send thee? Does physician-ownership affect referral patterns to ambulatory surgery centers? Health Aff (Millwood). 2008 May-Jun; 27(3):w165-74. Gabel JR, Fahlman C, Kang R, Wozniak G, Kletke P, Hay JW. PMID: 18349040.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    82. Asthma costs and utilization in a managed care organization. J Allergy Clin Immunol. 2008 Apr; 121(4):885-92.e5. Zeiger RS, Hay JW, Contreras R, Chen W, Quinn VP, Seal B, Schatz M. PMID: 18313133.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    83. Economic implications of entecavir treatment in suppressing viral replication in chronic hepatitis B (CHB) patients in China from a perspective of the Chinese Social Security program. Value Health. 2008 Mar; 11 Suppl 1:S11-22. Yuan Y, Iloeje U, Li H, Hay J, Yao GB. PMID: 18387054.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    84. Evaluation of the cost-effectiveness of entecavir versus lamivudine in hepatitis BeAg-positive chronic hepatitis B patients. J Manag Care Pharm. 2008 Jan-Feb; 14(1):21-33. Yuan Y, Iloeje UH, Hay J, Saab S. PMID: 18240879.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    85. A six-year study of diagnostic lower extremity imaging practice patterns and outcomes in the Veterans Affairs health care system. Int J Angiol. 2008; 17(2):78-82. Scranton RE, Dhingra R, Lawler EV, Yucel K, Guo A, Chittamooru SP, Gagnon DR, Hay JW, Gaziano JM. PMID: 22477392.
      View in: PubMed   Mentions:
    86. A review of the clinical and economic outcomes of imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Expert Opin Pharmacother. 2007 Nov; 8(16):2775-87. Carpiuc KT, Stephens JM, Botteman MF, Feng W, Hay JW. PMID: 17956198.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    87. The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: a propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database. Am Heart J. 2007 Aug; 154(2):267-77. Costanzo MR, Johannes RS, Pine M, Gupta V, Saltzberg M, Hay J, Yancy CW, Fonarow GC. PMID: 17643575.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    88. Cost effectiveness of adalimumab for the treatment of ankylosing spondylitis in the United Kingdom. Rheumatology (Oxford). 2007 Aug; 46(8):1320-8. Botteman MF, Hay JW, Luo MP, Curry AS, Wong RL, van Hout BA. PMID: 17545684.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    89. Economic burden of haematological adverse effects in cancer patients: a systematic review. Clin Drug Investig. 2007; 27(6):381-96. Liou SY, Stephens JM, Carpiuc KT, Feng W, Botteman MF, Hay JW. PMID: 17506589.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    90. Where's the value in health care? Value Health. 2006 May-Jun; 9(3):141-3. Hay JW. PMID: 16689706.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    91. Economic impact of antidiabetic medications and glycemic control on managed care organizations: a review of the literature. J Manag Care Pharm. 2006 Mar; 12(2):130-42. Stephens JM, Botteman MF, Hay JW. PMID: 16515371.
      View in: PubMed   Mentions: 10     Fields:    
    92. Comparing patient access to pharmaceuticals in the UK and US. Appl Health Econ Health Policy. 2006; 5(4):269-70; author reply 270-2. Hay JW. PMID: 17249843.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    93. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis. Pharmacoeconomics. 2006; 24(12):1221-32. Spalding JR, Hay J. PMID: 17129076.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    94. Cost and utilization impacts of oral antihistamines in the California Medi-Cal program. Value Health. 2005 Jul-Aug; 8(4):506-16. Hay JW, Leahy M. PMID: 16091028.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    95. Economic considerations for pertussis booster vaccination in adolescents. Pediatr Infect Dis J. 2005 Jun; 24(6 Suppl):S127-33. Hay JW, Ward JI. PMID: 15931140.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    96. Appropriate econometric methods for pharmacoeconometric studies of retrospective claims data: an introductory guide. J Manag Care Pharm. 2005 May; 11(4):344-8. Hay JW. PMID: 15871646.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    97. The cost effectiveness of cardiovascular medicines. Curr Atheroscler Rep. 2005 Mar; 7(2):79-80. Hay J. PMID: 15727719.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    98. Cost-effectiveness analysis of rizatriptan and sumatriptan versus Cafergot in the acute treatment of migraine. CNS Drugs. 2005; 19(7):635-42. Zhang L, Hay JW. PMID: 15984898.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    99. Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease. Pharmacoeconomics. 2005; 23(2):133-41. Hay JW, Sterling KL. PMID: 15748088.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    100. Medicare coverage and reimbursement of outpatient prescription drugs in the US: history, recent changes and outlook for the future. Appl Health Econ Health Policy. 2005; 4(1):9-14. Forrest S, Goetghebeur MM, Hay J. PMID: 16076234.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    101. Cost effectiveness of methylphenidate versus AMP/DEX mixed salts for the first-line treatment of ADHD. Expert Rev Pharmacoecon Outcomes Res. 2004 Dec; 4(6):625-34. Narayan S, Hay J. PMID: 19807536.
      View in: PubMed   Mentions: 5     Fields:    
    102. Evaluation and review of pharmacoeconomic models. Expert Opin Pharmacother. 2004 Sep; 5(9):1867-80. Hay JW. PMID: 15330725.
      View in: PubMed   Mentions: 6     Fields:    
    103. Using conjoint analysis to assess depression treatment preferences among low-income Latinos. Psychiatr Serv. 2004 Aug; 55(8):934-6. Dwight-Johnson M, Lagomasino IT, Aisenberg E, Hay J. PMID: 15292545.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    104. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis. Clin Infect Dis. 2004 Jul 01; 39(1):20-8. Purdy KW, Hay JW, Botteman MF, Ward JI. PMID: 15206048.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    105. Cost-effectiveness of primary implanted cardioverter defibrillator for sudden death prevention in congestive heart failure. Cardiovasc Drugs Ther. 2004 Mar; 18(2):161-70. Chen L, Hay JW. PMID: 15162078.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    106. Evaluating the cost-effectiveness of statins. J Manag Care Pharm. 2004 Jan-Feb; 10(1):79-81. Hay JW. PMID: 14720107.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    107. Cost-effectiveness analysis of pharmaceutical care in a medicare drug benefit program. Value Health. 2003 Jul-Aug; 6(4):425-35. Etemad LR, Hay JW. PMID: 12859583.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    108. Hospital cost drivers: an evaluation of 1998-2001 state-level data. Am J Manag Care. 2003 Jun; 9 Spec No 1:SP13-24. Hay JW. PMID: 12817612.
      View in: PubMed   Mentions: 9     Fields:    
    109. Understanding the underlying drivers of inpatient cost growth: a literature review. Am J Manag Care. 2003 Jun; 9 Spec No 1:SP3-12. Goetghebeur MM, Forrest S, Hay JW. PMID: 12817611.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    110. Examining the value and quality of health economic analyses: implications of utilizing the QHES. J Manag Care Pharm. 2003 Jan-Feb; 9(1):53-61. Ofman JJ, Sullivan SD, Neumann PJ, Chiou CF, Henning JM, Wade SW, Hay JW. PMID: 14613362.
      View in: PubMed   Mentions: 73     Fields:    Translation:Humans
    111. Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care. 2003 Jan; 41(1):32-44. Chiou CF, Hay JW, Wallace JF, Bloom BS, Neumann PJ, Sullivan SD, Yu HT, Keeler EB, Henning JM, Ofman JJ. PMID: 12544542.
      View in: PubMed   Mentions: 78     Fields:    Translation:Humans
    112. Effects of ambulatory-care pharmacist consultation on mortality and hospitalization. Am J Manag Care. 2003 Jan; 9(1):45-56. Yuan Y, Hay JW, McCombs JS. PMID: 12549814.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    113. Expensive conditions. Health Aff (Millwood). 2002 Nov-Dec; 21(6):271-2; author reply 272. Hay JW. PMID: 12442870.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    114. Cost-effectiveness of preventive occupational therapy for independent-living older adults. J Am Geriatr Soc. 2002 Aug; 50(8):1381-8. Hay J, LaBree L, Luo R, Clark F, Carlson M, Mandel D, Zemke R, Jackson J, Azen SP. PMID: 12164994.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    115. Embedding health-promoting changes into the daily lives of independent-living older adults: long-term follow-up of occupational therapy intervention. J Gerontol B Psychol Sci Soc Sci. 2001 Jan; 56(1):P60-3. Clark F, Azen SP, Carlson M, Mandel D, LaBree L, Hay J, Zemke R, Jackson J, Lipson L. PMID: 11192339.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    116. Management of acute otitis media. Evid Rep Technol Assess (Summ). 2000 Jun; (15):1-4. Marcy M, Takata G, Chan LS, Shekelle P, Mason W, Wachsman L, Ernst R, Hay JW, Corley PM, Morphew T, Ramicone E, Nicholson C. PMID: 10932957.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    117. Commentary: pharmacoeconomics and outcomes research: expanding the healthcare "outcomes" market. Value Health. 2000 May-Jun; 3(3):181-5. Hay JW, Yu WM. PMID: 16464182.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    118. Cost-effectiveness analysis of alternative factor VIII products in treatment of haemophilia A. Haemophilia. 1999 May; 5(3):191-202. Hay JW, Ernst RL, Kessler CM. PMID: 10444287.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    119. Panel 2: methodological issues in conducting pharmacoeconomic evaluations--modeling studies. Value Health. 1999 Mar-Apr; 2(2):78-81. Hay J, Jackson J. PMID: 16674337.
      View in: PubMed   Mentions: 5     Fields:    
    120. Pharmacoeconomics of lipid-lowering agents for primary and secondary prevention of coronary artery disease. Pharmacoeconomics. 1999 Jan; 15(1):47-74. Hay JW, Yu WM, Ashraf T. PMID: 10345158.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    121. The Kaiser Permanente/USC Patient Consultation Study: change in use and cost of health care services. Am J Health Syst Pharm. 1998 Dec 01; 55(23):2485-99. McCombs JS, Liu G, Shi J, Feng W, Cody M, Parker JP, Nichol MB, Hay JW, Johnson KA, Groshen SL, Nye MT. PMID: 9853633.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    122. From research into practice: how should healthcare organizations/governments decide about lipid therapy and who will pay? Reactor panel and open forum. Value Health. 1998 Nov; 1(4):243-50. Langley PC, Hay JW, Schwartz JS, Smith SC, McKenney J. PMID: 16674549.
      View in: PubMed   Mentions:    Fields:    
    123. Commentary on Langley and McKenney Papers. Value Health. 1998 Nov; 1(4):216-7. Ashraf T, Langley PC, Hay JW, Bonnette J, McKenney JM. PMID: 16674542.
      View in: PubMed   Mentions:    Fields:    
    124. A direction for Value in Health. Value Health. 1998 Sep; 1(3):149-54. Hay JW, Ernst RL. PMID: 16674344.
      View in: PubMed   Mentions:    Fields:    
    125. The ISPOR Lipid Conference: pharmacoeconomics and outcomes modeling issues. Value Health. 1998 Sep; 1(3):155-8. Hay JW, Schwartz JS. PMID: 16674345.
      View in: PubMed   Mentions:    Fields:    
    126. Economic modeling and sensitivity analysis. Value Health. 1998 Sep; 1(3):187-93. Hay JW. PMID: 16674351.
      View in: PubMed   Mentions: 5     Fields:    
    127. Introduction to the ISPOR Lipid Conference. Value Health. 1998 Jul-Aug; 1(2):95-9. Hay JW, Schwartz JS. PMID: 16674353.
      View in: PubMed   Mentions: 1     Fields:    
    128. The costs and social burdens of Alzheimer disease: what can and should be done? Alzheimer Dis Assoc Disord. 1997 Dec; 11(4):181-3. Hay JW, Sano M, Whitehouse PJ. PMID: 9437434.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    129. Occupational therapy for independent-living older adults. A randomized controlled trial. JAMA. 1997 Oct 22-29; 278(16):1321-6. Clark F, Azen SP, Zemke R, Jackson J, Carlson M, Mandel D, Hay J, Josephson K, Cherry B, Hessel C, Palmer J, Lipson L. PMID: 9343462.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansCTClinical Trials
    130. Cognitive function and the costs of Alzheimer disease. An exploratory study. Arch Neurol. 1997 Jun; 54(6):687-93. Ernst RL, Hay JW, Fenn C, Tinklenberg J, Yesavage JA. PMID: 9193203.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    131. Economic research on Alzheimer disease: a review of the literature. Alzheimer Dis Assoc Disord. 1997; 11 Suppl 6:135-45. Ernst RL, Hay JW. PMID: 9437458.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    132. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease. Am J Cardiol. 1996 Aug 15; 78(4):409-14. Ashraf T, Hay JW, Pitt B, Wittels E, Crouse J, Davidson M, Furberg CD, Radican L. PMID: 8752184.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    133. Cost of lipid-lowering statin drugs. Am J Cardiol. 1996 Jan 15; 77(2):225-6. Gotto AM, Hay JW. PMID: 8546104.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    134. Measuring the impact of patient counseling in the outpatient pharmacy setting: the research design of the Kaiser Permanente/USC patient consultation study. Clin Ther. 1995 Nov-Dec; 17(6):1188-206. McCombs JS, Cody M, Besinque K, Borok G, Ershoff D, Groshen S, Hay J, Johnson KA, Nichol MB, Nye MT. PMID: 8750409.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    135. Is pharmacy's vision of the future too narrow? Am J Health Syst Pharm. 1995 Jun 01; 52(11):1208-14. McCombs JS, Nichol MB, Johnson KA, Hay JW, Ebin VJ, Lawrence GD, Schneider JS. PMID: 7656110.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    136. The US economic and social costs of Alzheimer's disease revisited. Am J Public Health. 1994 Aug; 84(8):1261-4. Ernst RL, Hay JW. PMID: 8059882.
      View in: PubMed   Mentions: 82     Fields:    Translation:Humans
    137. Incorrectly framing pharmacoeconomics. Am J Hosp Pharm. 1994 Jun 01; 51(11):1473-4. Hay JW. PMID: 7942883.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    138. Comment: Evaluation of pharmacoeconomic studies: utilization of a checklist. Ann Pharmacother. 1994 Apr; 28(4):539. Hay JW. PMID: 8038486.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    139. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol. 1992 Jun; 14(4):309-17. Hay JW, Hay AR. PMID: 1607607.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    140. Inflammatory bowel disease: medical cost algorithms. J Clin Gastroenterol. 1992 Jun; 14(4):318-27. Hay AR, Hay JW. PMID: 1607608.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    141. An economic evaluation of lovastatin for cholesterol lowering and coronary artery disease reduction. Am J Cardiol. 1991 Apr 15; 67(9):789-96. Hay JW, Wittels EH, Gotto AM. PMID: 1901436.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    142. Cost-effectiveness of alpha-1 antitrypsin replacement therapy in treatment of congenital chronic obstructive pulmonary disease. Am J Public Health. 1991 Apr; 81(4):427-33. Hay JW, Robin ED. PMID: 1900677.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    143. Cost-benefit analysis of Haemophilus influenzae type b prevention: conjugate vaccination at eighteen months of age. Pediatr Infect Dis J. 1990 Apr; 9(4):246-52. Hay JW, Daum RS. PMID: 2110651.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    144. Medical costs of coronary artery disease in the United States. Am J Cardiol. 1990 Feb 15; 65(7):432-40. Wittels EH, Hay JW, Gotto AM. PMID: 2305682.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    145. Econometric issues in modeling the costs of AIDS. Health Policy. 1989; 11(2):125-45. Hay JW. PMID: 10292981.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    146. Cost-effectiveness of three transdermal nitroglycerin controlled-release systems. Clin Ther. 1988; 10(4):450-5. Hay JW. PMID: 3152619.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    147. The economic costs of Alzheimer's disease. Am J Public Health. 1987 Sep; 77(9):1169-75. Hay JW, Ernst RL. PMID: 3113273.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    148. Cost-benefit analysis of two strategies for prevention of Haemophilus influenzae type b infection. Pediatrics. 1987 Sep; 80(3):319-29. Hay JW, Daum RS. PMID: 3114708.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsPHPublic Health
    149. The Rand Health Insurance Study: a summary critique. Med Care. 1987 Feb; 25(2):148-56. Welch BL, Hay JW, Miller DS, Olsen RJ, Rippey RM, Welch AS. PMID: 3102860.
      View in: PubMed   Mentions: 1     Fields:    
    150. Medicare pricing mechanisms for physician services: an overview of alternative approaches. Med Care Rev. 1986; 43(1):59-100. Hanna RF, Ward TJ, Chow DS, Lagana SM, Moreira RK, Emond JC, Weintraub JL, Prince MR, Sloan FA, Hay JW. PMID: 10301042.
      View in: PubMed   Mentions:
    151. Cost-effectiveness of two transdermal nitroglycerin controlled-release systems. Clin Ther. 1985; 8(1):35-40. Hay JW, Hill WL. PMID: 3938682.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    152. Physician pricing and health insurance reimbursement. Health Care Financ Rev. 1983; 5(2):69-80. Yett DE, Der W, Ernst RL, Hay JW. PMID: 10310530.
      View in: PubMed   Mentions: 2     Fields:    
    153. Blue Shield plan physician participation. Health Care Financ Rev. 1981; 2(4):9-24. Yett DE, Der W, Ernst RL, Hay JW. PMID: 10309468.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    Joel's Networks
    Concepts (568)
    Derived automatically from this person's publications.
    _
    Co-Authors (29)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _